Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,669 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lentivirus Infections Clear all
Completed Phase 1 Interventional

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Smoking Cessation Pilot for People Living With HIV (PLWH)

NCT04808609
View directory record Official record
Conditions
Smoking Cessation, Smoking, Smoking Behaviors, Smoking Reduction, Smoking, Tobacco, Smoking, Cigarette, Hiv, HIV/AIDS
Interventions
Lumme mobile phone application, Standard of Care
Device · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Nutrition Intervention in AIDS Wasting

NCT00006167
View directory record Official record
Conditions
HIV Wasting Syndrome
Interventions
oxandrolone, Progressive Resistance Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrEP2Prevent An Online PrEP Navigation and Activation Intervention

NCT05281393
View directory record Official record
Conditions
HIV Infections
Interventions
PrEPresent
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
16 Years to 26 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

NCT00440947
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

NCT00002208
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
View directory record Official record
Conditions
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
Interventions
cenicriviroc
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

NCT00000844
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
15
States / cities
Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

NCT00076999
View directory record Official record
Conditions
HIV Infections
Interventions
TPV oral solution, RTV oral solution
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 18 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

The Use of Reiki for Patients With Advanced AIDS

NCT00032721
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Reiki; Subtle energy therapy
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

NCT03760458
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 11 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

NCT03016533
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Efficacy of Group Intervention to Reduce Stress Symptoms

NCT00611338
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, HIV Infections
Interventions
HIV Skills-based Prevention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

NCT00000738
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Nimodipine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Alternative Stress Management Approaches in HIV Disease

NCT00029237
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive-behavioral relaxation (Positively Living), Spiritual growth group, Focused Tai Chi
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

RAL-eve Study: Raltegravir Substitution Study

NCT00523237
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Reducing HIV & Domestic Violence Risk in Women Offenders

NCT00289939
View directory record Official record
Conditions
HIV Infections, Domestic Violence, Sexually Transmitted Diseases
Interventions
Motivational interviewing to reduce risk for HIV and DV
Behavioral
Lead sponsor
Multnomah County Health Department
Government
Eligibility
18 Years and older · Female only
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 28, 2006 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 9, 2026, 5:09 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Clinic-Community Bridge to Improve Health Outcomes for Abused Women Living With HIV/AIDS

NCT07553312
View directory record Official record
Conditions
Adult Women Living With HIV/AIDS, Intimate Partner Violence
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection

NCT00002092
View directory record Official record
Conditions
HIV Infections
Interventions
Cimetidine
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Enhancement by Poly-ICLC During HIV-1 Infection

NCT02071095
View directory record Official record
Conditions
HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions
Arm A: Poly-ICLC, Arm B: Normal Saline
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

NCT00942136
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Placebo, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2009 · Synced Oct 9, 2026, 5:09 AM EDT
Not listed Phase 2 Interventional

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

NCT00113412
View directory record Official record
Conditions
HIV Infections
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Oct 9, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581
View directory record Official record
Conditions
HIV Infections
Interventions
Oral BMS-663068 (pro-drug)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 9, 2026, 5:09 AM EDT